Phase I Study of BCMA CAR-T using instant manufacturing platform or traditional production process for relapsed/refractory multiple myeloma therapy

被引：0

作者：

Liu, Hui ^{[1
]}

Wang, Ting ^{[1
]}

Yang, Yazi ^{[1
]}

Feng, Ru ^{[1
]}

Li, Jiangtao ^{[1
]}

Zhang, Chunli ^{[1
]}

Bai, Jiefei ^{[1
]}

Ding, Yanping ^{[2
]}

Liu, Guanghua ^{[2
]}

Wu, Fei ^{[2
]}

Lu, Xinan ^{[2
]}

He, Ting ^{[2
]}

机构：

[1] Beijing Hosp, Beijing, Peoples R China

[2] Beijing Imunopharm Technol Co Ltd, Beijing, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-07

引用

页码：S5 / S5

页数：1

共 50 条

[1] BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma
Wang, Ting
Yang, Yazi
Ma, Lie
Feng, Ru
Li, Jiangtao
Zhang, Chunli
Bai, Jiefei
Ding, Yanping
Liu, Guanghua
Wu, Fei
Lu, Xinan
Feng, Shi
Li, Zhenling
He, Ting
Li, Jian
Liu, Hui
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
[2] CAR-T Therapy in Relapsed Refractory Multiple Myeloma
Ding, Hong
Wu, Yu
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (27) : 4362 - 4382
[3] Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <3 Days Using the High-Performance Platform
Liu, Hui
Wang, Ting
Yang, Yazi
Feng, Ru
Li, Jiangtao
Zhang, Chunli
Bai, Jiefei
Ding, Yanping
Liu, Guanghua
Wu, Fei
Lu, Xinan
Li, Jian
He, Ting
BLOOD, 2022, 140 : 10307 - 10308
[4] Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Fandrei, David
Seiffert, Sabine
Rade, Michael
Rieprecht, Susanne
Gagelmann, Nico
Born, Patrick
Wiemers, Thomas
Weidner, Heike
Kreuz, Markus
Schassberger, Tamara
Kossmann, Jannik
Mangold, Marlene
Fuerst, Daniel
Fischer, Luise
Baber, Ronny
Heyn, Simone
Wang, Song Yau
Bach, Enrica
Hoffmann, Sandra
Metzeler, Klaus H.
Herling, Marco
Jentzsch, Madlen
Franke, Georg-Nikolaus
Koehl, Ulrike
Friedrich, Maik
Boldt, Andreas
Reiche, Kristin
Platzbecker, Uwe
Vucinic, Vladan
Merz, Maximilian
BLOOD CANCER DISCOVERY, 2025, 6 (01): : 38 - 54
[5] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
Feng, Deming
Sun, Jian
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
[6] BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
Yan, Yuhan
Tu, Yixuan
Cheng, Qian
Zhang, Jian
Wang, Erhua
Deng, Zuqun
Yu, Yan
Wang, Liwen
Liu, Rui
Chu, Ling
Kang, Liqing
Liu, Jing
Li, Xin
JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
[7] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
Zhang, Xiaohui
Ouyang, Chenxi
Sun, Guofeng
Liu, Hongfeng
Qi, Junyuan
Suo, Xiaohui
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
[8] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
Yao, Xin
Zhu, Shigui
Huang, Jiaqi
Qu, Xiaoyan
Zhu, Judy
Wei, Yutian
Lan, Liping
Lv, Xiaoteng
Wu, Junfeng
Wang, Rirfei
Yang, Dingzhu
Zheng, Chengxiao
Zhao, DiJun
Fan, Lei
Huang, Fei
Lu, Hua
Zhang, Chaocan
Chen, Cheng
Li, Yanfeng
Ren, Jiaqiang
Zhang, Li
Humphries, Michael
Li, Jianyong
Yao, Yihong
BLOOD, 2019, 134
[9] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
Zhang, Hua
Gao, Lei
Liu, Li
Wang, Jishi
Wang, Sanbin
Gao, Li
Zhang, Cheng
Liu, Yao
Kong, Peiyan
Liu, Jia
He, Jiaping
Han, Yu
Shi, Hua
He, Yan
Ye, Xun
Zhao, Yi
Cao, Wei
Shen, Lianjun
Zhang, Xi
BLOOD, 2019, 134
[10] APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial
Li, Wenxiao
Hu, Yongxian
Zhang, Mingming
Lai, Xinyi
Zhao, Mengyu
Fu, Shan
Hong, Ruimin
Chang, Alex H.
Huang, He
BLOOD, 2024, 144 : 7229 - 7229

← 1 2 3 4 5 →